<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00557791</url>
  </required_header>
  <id_info>
    <org_study_id>ACU302</org_study_id>
    <nct_id>NCT00557791</nct_id>
  </id_info>
  <brief_title>Safety &amp; Efficacy Study Evaluating the Combination of Bevasiranib &amp; Lucentis Therapy in Wet AMD (CARBON)</brief_title>
  <acronym>CARBON</acronym>
  <official_title>A Phase 3, Randomized, Double-masked, Parallel-assignment and Dose-finding Study of Intravitreal Bevasiranib Sodium, Administered Every 8 Weeks as Maintenance Therapy Following Three Injections of Lucentis® Compared With Lucentis® Monotherapy Every 4 Weeks in Patients With Exudative Age-Related Macular Degeneration (AMD).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OPKO Health, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OPKO Health, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and effectiveness of three doses of
      intravitreal bevasiranib sodium as maintenance therapy for Age-Related Macular Degeneration
      following initiation of anti-VEGF therapy with three doses of Lucentis®.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study never initiated
  </why_stopped>
  <start_date>November 2009</start_date>
  <completion_date type="Anticipated">July 2012</completion_date>
  <primary_completion_date type="Anticipated">July 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary efficacy measure: The proportion of patients at week 60 in each group with a successful visual acuity outcome (as defined as avoidance of a 3, or more, line loss in vision).</measure>
    <time_frame>60 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time from tx initiation to 1st use of rescue</measure>
    <time_frame>60 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of change in VA from baseline to 60 weeks</measure>
    <time_frame>60 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients at week 60 with a 3, or more, line gain in vision</measure>
    <time_frame>60 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Age Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lucentis® (0.5 mg) every 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevasiranib (1.0 mg) every 8 weeks beginning at week 12, after pre-treatment with 3 injections of Lucentis® and initial priming doses of bevasiranib at weeks 2 &amp; 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevasiranib (2.0 mg) every 8 weeks beginning at week 12, after pre-treatment with 3 injections of Lucentis® and initial priming doses of bevasiranib at weeks 2 &amp; 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevasiranib (2.5 mg) every 8 weeks beginning at week 12, after pre-treatment with 3 injections of Lucentis® and initial priming doses of bevasiranib at weeks 2 &amp; 6.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevasiranib</intervention_name>
    <description>Three doses (1.0mg, 2.0mg, 2.5mg) of bevasiranib administered intravitreally every 8 weeks</description>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranibizumab</intervention_name>
    <description>Lucentis® (0.5 mg) administered intravitreally every 4 weeks.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Lucentis®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be age 50 years or older

          -  Patients must have predominantly classic, minimally classic or occult with no classic
             lesions secondary to Age Related Macular Degeneration.

          -  The study eye must have ETDRS best corrected visual acuity of 69 to 24 letters (20/40
             to 20/320 Snellen equivalent).

          -  Patients must be willing and able to return for scheduled monthly follow-up visits for
             two-years.

        Exclusion Criteria:

          -  Prior pharmacologic treatment for AMD in the study (patients can not have previously
             received Avastin®/Lucentis®, Macugen®, or any other anti-VEGF agents, steroid
             treatments, PDT, radiation treatment, or any experimental therapies for AMD in the
             study eye)

          -  Any intraocular surgery of the study eye within 12 weeks of screening

          -  Previous posterior vitrectomy of the study eye

          -  Advanced glaucoma or intraocular pressure above 22 mm Hg in the study eye despite
             treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naveed Shams, MD</last_name>
    <role>Study Director</role>
    <affiliation>SVP at Opko Health</affiliation>
  </overall_official>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2007</study_first_submitted>
  <study_first_submitted_qc>November 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2007</study_first_posted>
  <last_update_submitted>March 5, 2015</last_update_submitted>
  <last_update_submitted_qc>March 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2015</last_update_posted>
  <responsible_party>
    <name_title>Naveed Shams</name_title>
    <organization>Opko Health</organization>
  </responsible_party>
  <keyword>AMD</keyword>
  <keyword>ARMD</keyword>
  <keyword>Exudative Macular Degeneration</keyword>
  <keyword>Bevasiranib</keyword>
  <keyword>siRNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

